Research progress on the application of botulinum toxin type A in the treatment of myogenous temporomandibular disorders
10.12016/j.issn.2096-1456.2024.06.010
- Author:
CHEN Yifan
1
,
2
,
3
,
4
,
5
;
TANG Liangchen
1
,
2
,
3
,
4
,
5
;
CHEN Min’er
1
,
2
,
3
,
4
,
5
;
ZHANG Xiao
1
,
2
,
3
,
4
,
5
;
TANG Kuangyun
1
,
2
,
3
,
4
,
5
;
LI Zhiyong
1
,
2
,
3
,
4
,
5
Author Information
1. Maxillofacial Surgery, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine &
2. Clinical Research Center for Oral Diseases of Zhejiang Province &
3. Key Laboratory of Oral Biomedical Research of Zhejiang Province &
4. Cancer Center of Zhejiang University &
5. Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province
- Publication Type:Review
- Keywords:
botulinum toxin type A / myogenous temporomandibular disorders / temporomandibular disorders / masticatory muscles / myalgia / acetylcholine / adverse effects / clinical application
- From:
Journal of Prevention and Treatment for Stomatological Diseases
2024;32(6):470-474
- CountryChina
- Language:Chinese
-
Abstract:
Myogenous temporomandibular disorder (M-TMD) is one of the main subtypes of temporomandibular disorder (TMD) and typically manifests as masticatory myofascial pain; the incidence of TMD has been increasing annually in recent years. Botulinum toxin type A (BTX-A) is a potent neurotoxin produced by Clostridium botulinum. BTX-A inhibits the release of acetylcholine from the presynaptic membrane, thereby blocking neuromuscular junction signaling. The noncosmetic application of BTX-A in the oral and maxillofacial regions is a prominent research topic. In recent years, an increasing number of studies have focused on the application of BTX-A in the treatment of M-TMD. The results of a literature review revealed that an appropriate dose (10-50 U unilaterally) of BTX-A administered in a single injection into the masticatory muscles can effectively treat myalgia over a period of 3-6 months. Common adverse effects, such as masticatory weakness and facial paralysis, are transient and can be avoided by standardized injection techniques. However, there is a lack of standardized guidelines for injection techniques in clinical practice.
- Full text:2024061410283373784A型肉毒素治疗肌源性颞下颌关节紊乱病的研究进展.pdf
